They grew revenue 17% and still earned $300 million less. The buyback stays frozen until regulators say so, and that 'will take several quarters.'
Thesis: Revenue growth and expense discipline are real but the bottom line is absorbing $929 million in provision expense while sales volume goes flat. The 2022 vintage was outsized, delinquencies are rising sequentially across lower and mid FICO bands, and management pre-announced that incremental provisions come if Q1 delinquencies don't slow. The buyback catalyst is frozen behind a regulatory process management describes as taking 'several quarters,' capping any re-rating.
Verdict: SHORT — Conviction: MEDIUM
Catalyst: Q1 2024 delinquency trajectory. Management: 'if we don't see a slowing in delinquency rates between now and first quarter... we'll have to take incremental provisions.' Slowing DQs prove the seasoning thesis and could unpause the buyback at the January call.
Key Risk: Charge-offs stabilize at peak for two to three quarters instead of declining. Sales volume continues flat-to-negative, killing loan growth that funds the reserve build. Card misclassification resolution drags past 2024, keeping capital return frozen indefinitely.
The Tell: Unprompted admission on capital: 'We've got the Basel endgame that's on the horizon, CECL phase also impacting capital levels.' Management volunteered multiple regulatory capital headwinds while discussing buyback timing. Combined with 'several quarters to fully resolve' on card misclassification, they told you the buyback isn't coming soon without being asked directly.
Friction Level: MODERATE_FRICTION — Both sides agree charge-offs are rising and reserves are building. Bull says it's seasoning in an oversized but profitable 2022 vintage with one more quarter of confirmation needed. Bear says the trend is already sequential (30bps up QoQ), sales are flat, and management pre-announced incremental provisions if Q1 delinquencies don't slow.
Report not found
The report data is no longer available. Please return to the archive.